Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity

DOI10.2307/2532851zbMath0925.62458OpenAlexW2316222558WikidataQ45101960 ScholiaQ45101960MaRDI QIDQ4335592

Gina R. Petroni, Mark Conaway

Publication date: 26 April 1999

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2532851

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items

Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm, Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials, Ethical issues in oncology biostatistics, Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials, Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes, Graphical comparison of multivariate nonparametric location tests for restricted alternatives, A Bayesian Group Sequential Approach for Multiple Endpoints, Directed Walk Designs for Dose-Response Problems with Competing Failure Modes, Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity, A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases, Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials, Testing Statistical Hypotheses on Stochastic Ordering of Discrete Distributions, MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION